Targeted genomic integration and rearrangement using prime assembly
Although therapeutic genome editing holds great potential to remedy diverse inherited and acquired disorders, targeted installation of medium-to-large genomic modifications in therapeutically relevant cells remains challenging1. Here we develop prime assembly, an approach that permits DNA sequence assembly and integration in human cells leveraging CRISPR-targeted dual flap synthesis. This method enables RNA-programmable site-specific integration of single or double-stranded DNA fragments. Unlike homology-directed repair, prime assembly is similarly active in dividing and non-dividing cells. We applied prime assembly to perform targeted exon recoding, transgene integration and megabase-scale rearrangements, including at therapeutically relevant loci in primary human cells. Prime assembly expands the capabilities of genome engineering by enabling the targeted integration of medium to large-sized DNA sequences without relying on double-stranded DNA donors, nuclease-driven double-strand breaks or cell cycle progression. Prime assembly enables RNA-guided integration of medium-to-large DNA sequences in human cells without requiring double-strand breaks or cell cycle progression, and supports exon recoding, transgene insertion and megabase-scale rearrangements.
Authors
- Vivien A. C. Schoonenberg (ORCID: https://orcid.org/0000-0002-7865-7120)
- William Mannherz (ORCID: https://orcid.org/0000-0003-4472-7394)
- Gue‐Ho Hwang (ORCID: https://orcid.org/0000-0002-4201-0974)
- Nozomu Kawashima (ORCID: https://orcid.org/0000-0001-5700-4481)
- Jing Zeng (ORCID: https://orcid.org/0000-0001-8953-9042)
- Suneet Agarwal (ORCID: https://orcid.org/0000-0003-4910-3118)
- Basheer Becerra (ORCID: https://orcid.org/0000-0003-4403-7959)
- Sébastien Levesque (ORCID: https://orcid.org/0000-0002-1671-1929)
- Daniel E. Bauer (ORCID: https://orcid.org/0000-0001-5076-7945)
- Luca Pinello (ORCID: https://orcid.org/0000-0003-1195-9607)
- Vasil Toskov (ORCID: https://orcid.org/0009-0001-2131-344X)
- Timothy Barry
- Luke Homfeldt
Institutions
- Broad Institute (US)
- Boston Children's Hospital (US)
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Center for Cancer Research (US)
- Harvard Stem Cell Institute (US)
Publication Details
- Journal
- Nature
- Published
- 2026-09-16
- DOI
- https://doi.org/10.1038/s41586-026-11024-2
- Primary Topic
- CRISPR and Genetic Engineering
- Type
- article
- Field-Weighted Citation Impact
- 0.00